Vireo Health Trades Down On Q3 Results, CEO Sees 'Clear Path To Profitability'
Vireo posted a quarterly net loss of $14.6 million versus net income of $14,890 in the corresponding period of the prior year. The adjusted net loss for the quarter was $4.9 million, up from a loss of $2 million year-over-year.
Vireo disclosed adjusted EBITDA loss of $5.9 million for the quarter, compared to adjusted EBITDA income of $182,082 in the comparable quarter of 2018.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
"We continued gaining sales momentum in our Maryland and Pennsylvania markets during the third quarter, and we also began seeing the benefits of capacity upgrades in our recently acquired Arizona business," founder and CEO Kyle Kingsley, M.D. said in a statement.
"Near-term profitability has been impacted by the under absorption of overhead costs in early stage markets where revenues are just beginning, but we're anticipating performance improvement in the coming quarters, especially given the positive demand trends and patient enrollment growth we're experiencing across most of our operating footprint."
“With virtually no debt, we control our own destiny and our lean operations and disciplined approach to capital allocation provide us a clear path to profitability,” Kingsley said.
Vireo shares were down 5.47% at $1.21 at the time of publication Wednesday.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.